Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL

被引：0
|
作者：
Tu, Sanfang [1 ]
Zhou, Lijuan [1 ]
Huang, Rui [1 ]
He, Yanjie [1 ]
Zhou, Xuan [1 ]
Yang, Jilong [1 ]
Hu, Yuxing [1 ]
Zhang, Honghao [1 ]
Chang, Lung-Ji [2 ,3 ]
Li, Yuhua [1 ]
机构：
[1] Southern Med Univ, Zhujiang Hosp, Dept Hematol, Guangzhou, Peoples R China
[2] Univ Elect Sci & Technol China, Sch Med, Chengdu, Peoples R China
[3] Geno Immue Med Inst, Shenzhen, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186308
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients
    Tu, Sanfang
    Zhou, Lijuan
    Huang, Rui
    Zhou, Xuan
    Yang, Jilong
    He, Yanjie
    Hu, Yuxing
    Zhang, Honghao
    Xie, Xiaoling
    Li, Yuhua
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1437 - 1440
  • [2] CD19 CAR-T Cell Therapy in Children with Relapsed and Refractory B-ALL
    Molostova, Olga
    Shelikhova, Larisa
    Muzalevsky, Yakov
    Kazachenok, Alexey
    Khismatullina, Rimma
    Abugova, Julia
    Kurnikova, Elena
    Trakhtman, Pavel
    Pershin, Dmitry
    Zubachenko, Viktoria
    Fadeeva, Maria
    Popov, Alexander M.
    Illarionova, Olga
    Miakova, Natalia
    Litvinov, Dmitry
    Novichkova, Galina
    Maschan, Alexey
    Maschan, Michael
    BLOOD, 2021, 138
  • [3] Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
    Lihong An
    Yuehui Lin
    Biping Deng
    Zhichao Yin
    Defeng Zhao
    Zhuojun Ling
    Tong Wu
    Yongqiang Zhao
    Alex H. Chang
    Chunrong Tong
    Shuangyou Liu
    BMC Cancer, 22
  • [4] Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CART therapy
    An, Lihong
    Lin, Yuehui
    Deng, Biping
    Yin, Zhichao
    Zhao, Defeng
    Ling, Zhuojun
    Wu, Tong
    Zhao, Yongqiang
    Chang, Alex H.
    Tong, Chunrong
    Liu, Shuangyou
    BMC CANCER, 2022, 22 (01)
  • [5] Factors Associated with Survival and Severe Cytokine Release Syndrome of Patients with Relapsed/Refractory B-ALL Receiving CD19 CAR-T Cell Therapy
    Li, Xi
    Luo, Chengxin
    Xu, Shuangnian
    Ma, Yanni
    Chen, Jieping
    BLOOD, 2020, 136
  • [6] Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
    Li, Xin
    Liu, Mei-Jing
    Mou, Nan
    Yang, Zhen-Xing
    Wang, Jia
    Mu, Juan
    Zhu, Hai-Bo
    Deng, Qi
    ONCOLOGY LETTERS, 2021, 22 (05)
  • [7] Superior Outcomes in Relapsed/Refractory Childhood B-ALL Than Adult Patients with CD19 CAR-T Cell Therapy: A Single-Center Pilot Prospective Study of 23 Patients
    Li, Tingting
    Luo, Luting
    Ren, Jinhua
    Luo, Xiaofeng
    Zheng, Zhihong
    Zheng, Hao
    Chen, Zhizhe
    Huang, Gangxiong
    Yang, Ting
    Hu, Jianda
    BLOOD, 2019, 134
  • [8] Successful Anti-CD 19 CAR-T Cell Therapy in Jehovah Witness Patient with Relapsed Refractory B-ALL
    Leal, Jordan
    Rodriguez, Liza
    Kus, Crissy
    Appenfeller, Allison
    Ganguly, Siddhartha
    McGuirk, Joseph P.
    Abhyankar, Sunil
    Singh, Anurag
    Lin, Tara
    Shune, Leyla
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S379 - S379
  • [9] SAFETY AND EFFICACY COMPARISON OF HUMANIZED CD19 CAR-T VERSUS BLINATUMOMAB THERAPY FOR RELAPSED/REFRACTORY B-ALL PATIENTS
    Wang, Kexin
    Jiang, Songfu
    Hu, Yongxian
    Huang, He
    BONE MARROW TRANSPLANTATION, 2024, 59 : 199 - 200
  • [10] Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy
    Wang, Yu
    Xue, Yu-juan
    Zuo, Ying-xi
    Jia, Yue-ping
    Lu, Ai-dong
    Zeng, Hui-min
    Zhang, Le-ping
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
12345